Short pulse antiretroviral therapy at HIV seroconversion:A multi-centre randomised trial of therapeutic intervention at primary HIV-1 infection. Tratamiento antirretroviral en pulsos cortos en la seroconversión por el VIH: ensayo clínico aleatorizado, multicéntrico, de intervención terapéutica en la infección primaria por VIH-1. - SPARTAC

Imperial College0 个研究点目标入组 371 人开始时间: 2007年5月23日最近更新: 2019年6月30日

适应症

试验速览

暂无简介。

•1. Have reached the age of consent in their country for participating in a clinical study
•2. Are confirmed primary HIV infection by at least one of the following criteria:
•- HIV positive antibody test within 6 months of an HIV negative antibody test
•- HIV antibody negative with positive RT-PCR test
•- Test incident at low level (<0.6) using detuned assay (must be subtype B)
•- Equivocal HIV antibody test supported by a repeat test within a 2 week period showing a rising optical density
•- Have clinical manifestations of symptomatic HIV seroconversion illness supported by antigen positivity and <4 bands on Western Blot
•3. Are able and willing to give written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1. Pregnant
•2. Unlikely to comply with protocol, and in particular adhere to therapeutic regimen
•3. Likely to use narcotics during the study period
•4. Antiretroviral therapy is indicated
•5. Antiretroviral therapy is contraindicated

发起方

Imperial College